Quick Answer
Alto Neuroscience, Inc. reported R&D Expense of $45.62 million for fiscal year 2025.
Alto Neuroscience, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $45.62M | -2.9% |
| 2024 | $47.00M | +55.1% |
| 2023 | $30.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.53M | -19.4% | -19.8% |
| June 30, 2025 | $13.12M | -0.5% | +31.6% |
| March 31, 2025 | $9.97M | +0.2% | -23.6% |
| September 30, 2024 | $13.06M | +63.9% | -0.9% |
| June 30, 2024 | $13.18M | +86.4% | +32.5% |
| March 31, 2024 | $9.95M | +77.4% | +24.9% |
| September 30, 2023 | $7.97M | — | +12.7% |
| June 30, 2023 | $7.07M | — | +26.1% |
- Alto Neuroscience, Inc. showed a decrease of -2.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Alto Neuroscience, Inc.’s r&d expense has grown by 50.6% (from $30.29 million to $45.62 million).
- The most recent figure is from Alto Neuroscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: